Loading...
Generating destination analysis
Catalyst Play
Featured in “Three Biotech Stocks to Buy Before ASCO's Biggest Data Drop”
ASCO May 29
Beam Therapeutics pioneered base editing — next-generation gene editing that rewrites DNA without cutting it. Their precision approach dramatically reduces off-target effects. Phase 1/2 oncology data is imminent at ASCO. If it works, base editing becomes the new standard for genetic medicine.
The catalyst: The American Society of Clinical Oncology (ASCO) annual meeting — May 29 to June 2 in Chicago — is the most important event in cancer drug development. Over 40,000 oncology professionals gather for late-stage clinical trial data presentations that routinely move biotech stocks 30–50% in a single session. These three companies have the most anticipated data readouts at ASCO 2026, and the results will determine their trajectory for years.
Compass Direction
Earnings IntelligenceAI-Powered
Loading earnings analysis...
Compass Score
Favorable
Key Numbers
Market Cap
$3B
P/E
N/A
Revenue Growth
0.0%
Gross Margin
N/A
ROE
N/A
About Beam Therapeutics
Beam Therapeutics is a small-cap biotech company listed on the NASDAQ, positioned as a pure-play investment vehicle for the biotech and genomics megatrend. Base editing platform with differentiated gene-editing pipeline. With a $3B market capitalization and no current profitability, Beam Therapeutics has delivered revenue headwinds with revenue moving 0% over the past year.
Expert Coverage
Unlock Full BEAM Analysis
Expert analysis and coverage for Beam Therapeutics
Upgrade to CompassFull access to 500+ ratings • $9/month
Price & Technical Analysis
Price50 DMA200 DMA
Price vs 200DMA
DMA Convergence
50 DMA
200 DMA
Rating last updated: 2026-05-14
More in Biotech & Genomics
LLY
Eli Lilly and Company
92
True North
Mixed
Pharma giant leading the GLP-1 revolution with Mounjaro and Zepbound weight-loss drugs.
NYSE
MCap $750BRev +32%P/E 65ALNY
Alnylam Pharmaceuticals
90
True North
Pure Play
RNA interference therapeutics leader with approved treatments for rare diseases.
NASDAQ
MCap $30BRev +40%CRSP
CRISPR Therapeutics
89
True North
Pure Play
Pioneer of CRISPR gene-editing therapy with first approved treatment for sickle cell disease.
NASDAQ
MCap $5BRev +350%DXCM
DexCom Inc.
89
True North
Pure Play
Continuous glucose monitoring leader expanding beyond diabetes management.
NASDAQ
MCap $35BRev +20%P/E 55